Previous 10 | Next 10 |
home / stock / cslly / cslly news
2024-01-03 10:19:29 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Drugmakers reportedly planning to raise p...
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe PR Newswire - Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - ...
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster PR Newswire Study conducted by Meiji Seika Pharma in Japan Dat...
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance PR Newswire These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living wi...
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B PR Newswire HEMGENIX ® is the first and ...
2023-11-29 07:40:38 ET More on uniQure uniQure: AMT-130 Data And Other Catalysts In H2 2023 uniQure to cut over 50% of research projects in strategic review uniQure cleared to start U.S. trial for gene therapy Seeking Alpha’s Quant Rating on uniQure ...
2023-11-28 14:14:56 ET More on Arcturus, CSL, etc. CSL Limited: Positive Capital Return And Earnings Growth Expectations From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Arcturus: COVID Vaccine Approval Shots In Japan And Europe Key ...
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults PR Newswire Exclusive Partner in Japan , Meiji Seika Pharma advances regulatory approval ...
Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need First ...
2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligenc...
PHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching studen...